Healthcare Bullish Stocks: Synta Pharmaceuticals (NASDAQ:SNTA), TherapeuticsMD Inc (NYSEMKT:TXMD), Cell Therapeutics Inc (NASDAQ:CTIC), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company’s Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock performance was 10.07% in last session and finished the day at $4.48. Traded volume was 1.87million shares in the last session and the average volume of the stock remained 2.61million shares. The beta of the stock remained 2.93. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) insider ownership is 10.10%.

TherapeuticsMD Inc. (NYSEMKT:TXMD)’s drug candidate for the treatment of Vulvar Vaginal Atrophy – TX 004-HR – has proven to be a “non-irritant” following a 28-day repeated application to the vaginal mucosa in a rabbit irritation study. TherapeuticsMD Inc (NYSEMKT:TXMD) rose 6.48 percent to $4.93 Wednesday on volume of 1.93million shares. The intra-day range of the stock was $4.71 to $5.15. TherapeuticsMD Inc (NYSEMKT:TXMD) has a market capitalization of $715.18million.

Cell Therapeutics Inc (NASDAQ:CTIC) got a thumbs up sign from rating agency WallachBeth and Roth Capital during the past few weeks, after the bio tech firm reported solid progress in its full year 2013 and 4Q13 operational results. Cell Therapeutics Inc (NASDAQ:CTIC)’s stock on Apr 09, 2014 reported a increase of 6.10% to the closing price of $3.48. Its fifty two weeks range is $0.97 -$4.25. The total market capitalization recorded $520.67million. The overall volume in the last trading session was 2.10million shares. In its share capital, CTIC has 149.61million outstanding shares.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a top biotech name that was sold off to the tune of a large 8.16%. Its new drug VX809 has a 50% chance of succeeding in Phase III trials. In February 2013, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) began two six-month, international Phase III clinical trials of Kalydeco and VX-809 in people with two copies of the Delta F508 mutation ages 12 and older. On Wednesday, shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) advanced 7.04% to close the day at $69.95. Company return on investment (ROI) is -33.00% and its monthly performance is recorded as -11.67%. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) quarterly revenue growth is -7.02%.